Craft

Advanced
Arvinas

Arvinas

Stock Price

$27.5

2024-10-29

Market Capitalization

$1.9 B

2024-10-29

Revenue

$262.6 M

FY, 2025

Arvinas Summary

Company Summary

Overview
Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases. The Company's main product is PROTAC, which degrades and removes disease-causing proteins.
Type
Public
Status
Active
HQ
New Haven, CT, US | view all locations
Website
http://arvinas.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Timothy Shannon, Chairman of the Board

    • Sharvari Apte

      Sharvari Apte, Vice President of Global and US Commercial Analytics

      • Janice Kapty, Vice President, Estrogen Receptor Global Asset Lead

        • Paul McInulty

          Paul McInulty, Senior Vice President, Regulatory Affairs

          LocationsView all

          1 location detected

          • New Haven, CT HQ

            United States

            5 Science Park

          Arvinas Financials

          Summary Financials

          Revenue (Q1, 2026)
          $15.6M
          Net income (Q1, 2026)
          ($57.6M)
          Cash (FY, 2025)
          $142.9M
          EBIT (Q1, 2026)
          ($63.8M)
          Enterprise value
          $1.8B

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX